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Open access undBackground and purpose: Recent data suggest that in vitro and in vivo derived hypoxia gene-expression
signatures have prognostic power in breast and possibly other cancers. However, both tumour hypoxia
and the biological adaptation to this stress are highly dynamic. Assessment of time-dependent gene-
expression changes in response to hypoxia may thus provide additional biological insights and assist
in predicting the impact of hypoxia on patient prognosis.
Materials and methods: Transcriptome proﬁling was performed for three cell lines derived from diverse
tumour-types after hypoxic exposure at eight time-points, which include a normoxic time-point.
Time-dependent sets of co-regulated genes were identiﬁed from these data. Subsequently, gene ontology
(GO) and pathway analyses were performed. The prognostic power of these novel signatures was
assessed in parallel with previous in vitro and in vivo derived hypoxia signatures in a large breast cancer
microarray meta-dataset (n = 2312).
Results: We identiﬁed seven recurrent temporal and two general hypoxia signatures. GO and pathway
analyses revealed regulation of both common and unique underlying biological processes within these
signatures. None of the new or previously published in vitro signatures consisting of hypoxia-induced
genes were prognostic in the large breast cancer dataset. In contrast, signatures of repressed genes, as
well as the in vivo derived signatures of hypoxia-induced genes showed clear prognostic power.
Conclusions: Only a subset of hypoxia-induced genes in vitro demonstrates prognostic value when eval-
uated in a large clinical dataset. Despite clear evidence of temporal patterns of gene-expression in vitro,
the subset of prognostic hypoxia regulated genes cannot be identiﬁed based on temporal pattern alone. In
vivo derived signatures appear to identify the prognostic hypoxia induced genes. The prognostic value of
hypoxia-repressed genes is likely a surrogate for the known importance of proliferation in breast cancer
outcome.
 2012 Elsevier Ireland Ltd.Open access under the Elsevier OA license.
Radiotherapy and Oncology 102 (2012) 436–443Poor oxygenation (hypoxia) is a ubiquitous feature of human
tumours and exhibits a highly dynamic spatial and temporal distri-
bution both within and between patients [1,2]. Hypoxia is strongly
associated with tumour development, growth, invasiveness, resis-
tance to therapy, and contributes to poor prognosis [3–6]. The cel-
lular response to hypoxia is complex and involves several distinct
oxygen sensing pathways [1], which have unique activation kinet-
ics and sensitivities to oxygen concentration. Variations in theion Oncology (MaastRO) Lab,
6, 6200MD Maastricht, The
sity.nl (M.H.W. Starmans).
er the Elsevier OA license.duration and severity of hypoxic stress therefore lead to substan-
tial phenotypic variations amongst genetically identical cells.
Gene-expression microarray technology provides the possibility
to study the function of the whole transcriptome by monitoring the
expression of tens of thousands of genes [7]. In oncology, this tech-
nique is often used to develop gene-expression proﬁles from pa-
tient tumour tissues as potential prognostic markers. These
proﬁles (gene signatures) can be used to identify different disease
subgroups [8] or to predict patient outcome [9,10] or treatment re-
sponse [11]. Gene-expression signatures might also point to path-
ways that are important for disease initiation and progression, but
extracting the underlying biological mechanisms highlighted by
these data remains challenging [7,12]. An alternative approach
uses gene-expression proﬁling of model systems to create
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logical process, which can be evaluated to understand the underly-
ing cellular pathways involved [7,10,13,14]. Several of these
hypothesis-driven signatures have shown prognostic value
[10,13,14].
Several groups, including our own, have identiﬁed hypoxia-
related gene sets from both in vitro [13,15] and in vivo data
[16,17] that demonstrate prognostic power. The in vitro hypoxia
signatures tested for prognostic value have been derived so far
from a single dataset [13] in which a series of cell lines was ex-
posed to two different hypoxia conditions (0% and 2%) for different
periods of time. Originally, a general hypoxia signature derived
from this series was shown to have prognostic value [13]. We later
showed that acutely responding genes, i.e. those induced at early
time-points, had better prognostic value [15]. However, in both
cases the performance of these in vitro derived signatures was
evaluated in a small number of patient gene-expression micro-
array datasets, studying a limited number of patients. In addition,
studies have identiﬁed hypoxia-regulated gene sets from other
in vitro microarray data, however these gene sets were not evalu-
ated in patient data to assess their prognostic value [18,19]. The
in vivo derived hypoxia signatures were extracted starting from a
single known hypoxia up-regulated gene [16] or a set of known
hypoxia up-regulated genes [17,20]. Signatures were then created
by selecting genes co-regulated with these known hypoxia genes
in gene-expression patient data. This approach does not assume
that the gene sets identiﬁed in this way are directly regulated by
hypoxia, but rather that their expression correlates with other
genes which are regulated by hypoxia. The in vivo derived signa-
tures have also shown high prognostic value on a limited series
of patient gene-expression data.
Here, we have investigated the prognostic value of in vitro and
in vivo derived hypoxia gene-expression data in a more compre-
hensive manner. Previous in vitro and in vivo hypoxia signatures
were tested in a much larger cohort of patients (n = 2311). In addi-
tion, we performed a large and comprehensive series of new
in vitro hypoxia time-course experiments at eight different time-
points in three cell lines. We hypothesize that the differences be-
tween slow and fast kinetics of hypoxic responses extracted from
these data may have differential contributions to patient progno-
sis. A set of time-dependent expression proﬁles was used to extract
gene-sets that showed different temporal responses to hypoxia.
These gene-sets were further studied for their molecular function,
involvement in known pathways and their prognostic value in pa-
tient datasets and compared to previously deﬁned hypoxia-related
signatures. Our data indicate that hypoxia regulated genes identi-
ﬁed in vivo are superior predictors of patient response.Table 1
Different time-proﬁles used to create gene clusters in relative log2-transformed units.
Time-point (h)
Gene Cluster 0 1 2 4 8 12 16 24Material and methods
Cell culture and hypoxic conditions
Exponentially growing prostate (DU145), colon (HT29) and
breast (MCF7) carcinoma cells were seeded on glass dishes in
McCoy, DMEM or RPMI media, respectively with 10% FCS and
transferred to a hypoxic chamber (MACS VA500, Don Whitley Sci-
entiﬁc, West-Yorkshire, UK) with atmosphere composition of 5%
H2, 5% CO2, 0.0% O2 and residual N2. Cells were exposed to nor-
moxia (time-point 0 h) and different times of severe hypoxia (1,
2, 4, 8, 12, 16 and 24 h, respectively).Cluster 1 0 1 1 1 1 1 1 1
Cluster 2 0 0 0 1 1 1 1 1
Cluster 3 0 0 0 0 0 1 1 1
Cluster 4 0 0 0 0 0 1 1 1
Cluster 5 0 0 0 1 1 1 1 1
Cluster 6 0 0 0 1 1 1 0 0
Cluster 7 0 1 1 1 1 1 1 1RNA isolation and microarrays
Total RNA was isolated for each time-point using RNeasy
(Qiagen, Hilden, Germany) following manufacturer’s speciﬁcations.
RNA quantity/quality was determined using an ND-1000spectrometer (NanoDrop Technologies, Wilmington, DE) and RNA
Nano LabChip kit on the 2100 BioAnalyzer (Agilent Technologies,
Palo Alto, CA). A summary of these data is provided in Supplemen-
tary Tables S1–S3. For each cell line, equal RNA amounts from three
independent experiments were pooled for each time-point to min-
imize experimental variability. Twenty nanograms pooled RNA
was processed according to the manufacturer’s protocols (Affyme-
trix, Santa Clara, CA) for 2-cycle ampliﬁcation and samples were
hybridized to Affymetrix HG-U133 Plus 2.0 GeneChips.Data processing
All analyses were performed in R (v2.12.2). Quality assurance
was performed for each time-series. Overall quality is within the
manufacturer’s standards (Supplementary Tables S4–S6). Data pro-
cessing was performed for each cell line separately using RMA (affy
package, v1.28.0) for pre-processing [21] and updated Entrez Gen-
eID annotation (hgu133plus2hsentrezgcdf package, v14.0.0) [22].
These data are available on www.cancerdata.org and have been
deposited in NCBI’s Gene Expression Omnibus [23] and are acces-
sible through GEO Series accession number GSE 29641.
An expression ﬁlter was applied to remove experimental noise.
A low-intensity threshold was set based on the chromosome-Y
gene intensities of the two female-derived cell lines (HT29 and
MCF7), as described previously [24]. The geneﬁlter package
(v1.32.0) was used to remove probes with a log2-transformed
expression value below 5 in at least 6/8 arrays. Only genes passing
this ﬁlter in all cell lines were retained.Principal Component Analysis (PCA)
To address whether the cell line datasets should be treated sep-
arately or could be analysed as one, a PCA was performed. PCA is
tool to reduce the dimensionality of the data. The ﬁrst three prin-
cipal components were used to visualize the data and the percent-
age variance explained was calculated.Extraction of dynamic gene lists
To extract dynamic gene-expression signatures a multi-step
extraction process was performed separately for each cell line.
First, genes showing differential expression across the time series
were identiﬁed. Genes were selected that showed a minimal
log2-transformed fold-change of ()1 (i.e. 2-fold in normal space),
in at least two consecutive time-points relative to normoxia. Venn
diagrams were drawn to compare cell lines (VennDiagram pack-
age, v1.0.0) [25]. Divisive hierarchical clustering was performed
using average Euclidean distance linkage (DIANA) (cluster package,
v1.13.3). Next, based on the observed expression patterns, seven
time-proﬁles were deﬁned (Table 1). These predeﬁned time-pro-
ﬁles were used as cluster centres in K-means clustering (amap
package, v0.8-5) to assign each gene to one proﬁle. Finally, the
three cell lines were compared to identify genes showing the same
time-dependent pattern in two out of three cell lines. Additionally,
438 Dynamic hypoxia gene-expression proﬁlingtwo general hypoxia responsive gene lists were generated: genes
showing an up-regulation in 2/3 cell lines and genes showing
down-regulation in 2/3 cell lines.Gene ontology (GO)
A GO-analysis was performed for the different gene lists using
the GOMiner tool [26]. Standard input settings were used with
1000 randomizations and 5 as smallest category size. Both p-values
and false discovery rate (FDR) were used to identify over-repre-
sented GO-categories. A false discovery rate (FDR) threshold of
0.1 was used to select GO-terms that were enriched per gene
cluster.Pathway analysis
In addition to the GO analysis pathway analyses were
performed for each of the different gene lists using the PANTHER
software tools [27]. P-values were used to identify over- and
under-represented pathways.Testing for prognostic value
Several public mRNA-abundance datasets of primary breast
cancer [9,11,28–37] were used to assess whether the dynamic gene
lists have prognostic capacity. Dataset pre-processing and annota-
tion were as described for the cell line data, with the addition of
housekeeping normalization (to the geometric mean of ACTB,
BAT1, B2M and TBP) and median scaling [38]. A multi-gene signa-
ture score was then calculated for each gene list as:
Score ¼
XN
n¼1
geneexpr;n ð1Þ
Here, N is the number of genes in the list, the parameter gen-
eexpr,n for a sample is 1 if the sample has a level of gene n above
the median for all samples in the dataset and 1 otherwise. This
score was used to median dichotomize the patients by dataset
and high/low expression patients were pooled across studies. Dif-
ferences in survival properties between the two groups wereFig. 1. (A) Gene-expression microarray intensity distributions of chromosome-Y genes (s
the three cell lines. (B) Scatterplot of the ﬁrst three principal components from Principa
colour/marker (d 0,  1, 2, N 4, 8,  12, 16, and j 24 h).assessed with Kaplan–Meier survival curves and Cox proportional
hazard ratio modelling followed by the Wald test (survival pack-
age, v2.36-5).
To complete the analysis a series of existing hypoxia gene-
expression signatures, including the 0% and 2% early signatures
[15], ‘Chi signature’ [13], Elvidge up and down gene sets [18],
Sorensen gene set [19], ‘Hu signature’ [16], the Winter metagene
[17] and the Buffa metagene [20], were also tested in the large
breast cancer dataset. Methodology was similar to the evaluation
of the gene lists as described in the above section.Results
Hypoxia time series
In order to develop more comprehensive in vitro hypoxia gene-
expression proﬁles, we exposed prostate (DU145), colon (HT29)
and breast (MCF7) cancer cell lines to severe hypoxia for 0, 1, 2,
4, 8, 12, 16, and 24 h and determined the transcriptome by micro-
array analysis. Expression of chromosome-Y genes across the three
cell lines was used to identify non-expressed genes that were sub-
sequently removed: two cell lines (HT29 and MCF7) are derived
from female patients, meaning that intensities of chromosome-Y
genes fall within the background noise. Fig. 1A shows that expres-
sion of the chromosome-Y genes in the female derived cell lines
are, as expected, amongst the lowest intensities, whereas for
(male) DU145 the chromosome-Y genes follow the same distribu-
tion pattern as the non-chromosome-Y genes.
A PCA was performed to assess the relationship between the
transcriptomes in all samples. Fig. 1B displays the ﬁrst three iden-
tiﬁed principal components, which encompass 88% of the variabil-
ity in the dataset. As expected, the three cell lines cluster as
individual sets. This conclusion was further supported by a K-
means (k = 3) clustering of samples, which divided them into three
groups according to cell line (data not shown). More importantly,
the PCA analysis clearly demonstrated the time-series pattern in
each of the three datasets with consecutive time-points clustering
closer together. Subsequent data analyses to determine hypoxia
regulated genes were thus performed separately on each cell line.olid curves) and non-chromosome-Y genes (dotted curves) across the time-series in
l Component Analysis. Each cell line and time-point is represented with a different
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In order to identify new hypoxia signatures, we ﬁrst extracted
the genes that showed differential expression across the time ser-
ies. Each hypoxic time-point was compared to normoxia and genes
altered at least 2-fold in two or more consecutive time-points were
retained. These genes were clustered to visualize temporal proﬁles
(Supplementary Fig. S1A) and the numbers of selected genes per
cell line were compared (Fig. 2A). In Supplementary Fig. S1B and
C heatmaps of the three time series are shown for the union and
intersection of the selected genes per cell line. Globally, the re-
sponses are similar across the three cell lines, however the speciﬁc
timing and magnitudes of changes are cell line dependent. Further-
more, for subsets of genes a clear response is observed in one/two
cell lines, without regulation in the other(s). However, expression
changes of the genes selected in all three cell lines are highly
similar.Fig. 2. Identiﬁcation of time-dependent gene-expression proﬁles upon hypoxic exposu
ordered by time-dependent clusters show distinct temporal regulation (B), clusters areThe heatmaps in Supplementary Fig. S1 show that in addition to
both induced and repressed genes, there are demonstrable tempo-
ral proﬁles of hypoxia-regulated genes. We deﬁned seven distinct
time-proﬁles (Table 1) and used k-means clustering to assign each
differentially regulated gene to one of these proﬁles. Fig. 2B shows
heatmaps of the differentially expressed genes per cell lines or-
dered by cluster. The ﬁnal seven lists are composed of genes that
fall within the same time cluster in at least two cell lines. In addi-
tion two global gene lists of induced and repressed genes were cre-
ated using the same criteria. Table 2 lists an overview of the
number of genes in each cluster for each cell line and the number
of genes in the ﬁnal signatures. The content of all nine of these new
in vitro derived hypoxia signatures are provided in Supplementary
Table S7. Gene-expression proﬁles for seven individual genes, one
from each cluster, and average expression proﬁles per cluster are
displayed in Fig. 3 and Supplementary Fig. S2, respectively.re. Both cell line dependent and independent genes were identiﬁed (A). Heatmaps
shown in the right colour bars.
Table 2
Number of genes identiﬁed in each gene proﬁle per cell line and in the ﬁnal gene lists.
Cell line
Gene list DU145 HT29 MCF7 Final
list
Fraction overlap: number
of genes in ﬁnal list,
divided by the average
of the number of genes
per cell line
Cluster 1 112 281 107 69 0.41
Cluster 2 306 650 344 246 0.57
Cluster 3 386 335 397 157 0.42
Cluster 4 162 265 356 95 0.36
Cluster 5 233 471 383 162 0.45
Cluster 6 35 129 165 14 0.13
Cluster 7 125 248 21 28 0.21
Up-regulated 804 1266 848 780 0.80
Down-regulated 555 1113 925 656 0.76
440 Dynamic hypoxia gene-expression proﬁlingGene ontology (GO) and pathway analysis of new signatures
To provide some biological context to the new signatures we
performed GO-analyses for each gene list and the numbers of en-
riched terms are listed in Supplementary Table S8. A complete list
of enriched GO terms is also listed in Supplementary Table S9. GO-
terms associated with the induced signatures and global list in-
clude apoptosis (GO:0006915, cluster 2, global up) and protein
folding (GO:0006457, cluster 3, global up). The down-regulated
gene lists are enriched for GO-categories including cell cycle
(GO:0007049, cluster 4, 5, global down) and transcription
(GO:0006350, cluster 5). A series of GO terms were found in several
clusters and in both induced and repressed lists; most of these
comprise cellular compartment terms. In addition a signiﬁcant
number of GO-terms were identiﬁed with the global induced lists
compared to the cluster lists. However many of these terms are
either from the cellular compartment category or related to terms
identiﬁed in the cluster lists. For example the term unfolded pro-
tein binding (GO:0051082) is related to the terms response to un-
folded protein (GO:0006986) and protein folding (GO:0006457)
enriched in cluster 2 and 3, respectively. A pathway analysis wasFig. 3. Gene-expression proﬁles for seven genes in each of thealso performed for each separate gene list. Results are provided
in Supplementary Table S10 and the pathways signiﬁcantly over-
or under-represented in at least 1 list are shown in Supplementary
Fig. S3. The pathways found enriched correspond with the GO anal-
ysis. Highest enrichment was found in the apoptosis signalling
pathway, angiogenesis and glycolysis for the up-regulated gene
lists and cell cycle for the down-regulated ones. Interestingly,
p53 signalling was enriched in both up- and down-regulated lists.Prognostic value of hypoxia gene signatures in breast cancer
Finally, we tested the prognostic potential of the new in vitro
derived hypoxic signatures and compared them with nine previ-
ously published in vitro and in vivo derived signatures. To do so,
we evaluated these signatures in a large number of breast cancer
gene-expression datasets comprising 2312 patients. This dataset
is many times larger than any other dataset used to evaluate hy-
poxia gene signatures and thus provides a robust test of their prog-
nostic power. For each signature, a score was calculated for each
patient (Eq. (1)), patients were dichotomized into high- and low-
score groups, and survival differences assessed. In Fig. 4A and Sup-
plementary Fig. S4A the Kaplan–Meier curves for all of the newly-
derived hypoxia signatures are displayed. Surprisingly, none of the
signatures consisting of hypoxia-induced genes are prognostic.
Similarly, our previously published early hypoxia signatures and
the original global hypoxia signature that were prognostic in a
smaller dataset, and two other in vitro derived hypoxia-induced
gene sets are not prognostic in this larger dataset (Supplementary
Fig. 4B). Interestingly however, the new repressed gene signatures
did show some prognostic value, e.g. cluster 5 dichotomizes pa-
tients with a hazard ratio (HR) of 1.35 (95% conﬁdence interval
[CI]: 1.18–1.56, p = 2.17  105, Wald test). Patient classiﬁcation
with the four different signiﬁcant repressed signatures is similar;
more than 75% (1760 patients) of the patients were classiﬁed iden-
tically by four out of ﬁve gene-sets (Fig. 4B). Further, genes identi-
ﬁed as hypoxia-repressed by Elvidge et al. [18] showed the same
prognostic value (HR: 1.28, CI: 1.11–1.47, p = 5.16  104, Wald
test).three cell lines, where each gene is from a distinct cluster.
Fig. 4. Evaluation of prognosticity of time-dependent hypoxia responses in a large breast cancer meta-dataset (n = 2312). Patients were assigned to low-score (blue curves)
and high-score (red curves) groups based on genes in global regulation lists (A) and Kaplan–Meier survival curves were drawn. Hazard ratios [HR] and p-values are from Cox
proportional hazard ratio modelling followed by the Wald test. Patient classiﬁcation with the ﬁve new prognostic gene lists shows large agreement (B). White/black indicate
patients assigned to the low-score/high-score group, respectively.
Fig. 5. Expression of subset of the Winter metagene that were selected as up-regulated (A) or as un-regulated (B) by hypoxia in vitro and evaluation of prognosticity of these
subsets in a large breast cancer meta-dataset (n = 2312). Patients were assigned to low-score (blue curves) and high-score (red curves) groups based on genes the up-
regulated subset (C) or un-regulated subset (D). Patient classiﬁcation with the full Winter metagene, up-regulated and un-regulated subset show distinct patterns (E).
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natures consisting of genes whose expression in vivo correlateswith known hypoxia-induced genes. In sharp contrast to the
in vitro derived signatures, these signatures show high prognostic
442 Dynamic hypoxia gene-expression proﬁlingpower in the large breast cancer meta-dataset (Supplementary
Fig. 4C). The ﬁrst published signature (Winter metagene), demon-
strated a hazard ratio of 1.58 (p = 1.38  1010, Wald test). To
investigate this discrepancy further, we evaluated the expression
of genes contained in the in vivo signatures in our new dataset.
For all three in vivo signatures, a large fraction of the genes show
clear up-regulation in the time-series (Supplementary Fig. S5).
However, a number of genes, especially in the two larger gene lists,
are not induced by hypoxia in any of the cell lines and a subset is
even consistently repressed. We therefore analysed separately the
prognostic power of genes that showed clear evidence of hypoxic
regulation in vitro from those that did not of one of these signa-
tures (Fig. 5A and B). Importantly, we ﬁnd that the hypoxia-regu-
lated genes in the in vivo signature retain clear prognostic power,
even when removed from those that were not regulated by our cri-
teria within the new dataset (Fig. 5C). However, the subset of genes
in the in vivo signature that were not hypoxia-regulated also con-
tribute to the prognostic power of this signature (Fig. 5D). This is
also reﬂected in the patient classiﬁcation (Fig. 5E), which is sub-
stantially different when using either of the subsets or the com-
plete signature.Discussion
In order to better deﬁne the potential prognostic value of gene-
expression signatures we have extended previous reported results
in three signiﬁcant ways. First, we conducted the largest and most
detailed transcriptome response to hypoxia published to date in
order to derive novel in vitro hypoxia signatures that better reﬂect
the nature of this stress. This dataset consists of three diverse cell
lines analysed at multiple time-points that allow expression of
genes regulated by different hypoxia responsive signalling path-
ways [1]. In both published and unpublished data, we have vali-
dated multiple hypoxia-regulated genes identiﬁed from these
time-series using quantitative RT-PCR [5,39,40]. Globally, re-
sponses are similar amongst the lines and for a subset of genes,
time-patterns are also similar. Discrepancies amongst the lines
with respect to meeting our criteria for regulation largely reﬂect
differences in magnitude of regulation, rather than in regulation
direction (Supplementary Fig. 1B). To some extent, the temporal
pattern is cell line dependent, as evidenced by a larger overlap be-
tween global gene lists than for individual signatures (Table 2). The
dynamic natures of these data highlight the limitations of employ-
ing a single time-point or cell line for determination of hypoxia-
responsive genes. This led us to extract a series of seven different
signatures consisting of genes with distinct temporal proﬁles to
evaluate in patient derived gene-expression data. Gene ontology
and pathway analyses suggest that each signature is likely to con-
tain genes that respond to both common and unique biological
processes including many previously implicated in hypoxia. Terms
linked to the unfolded protein response, ER stress, autophagy, cell
death and metabolism [1,41,42] were enriched in the induced sig-
natures, whereas terms linked to proliferation, RNA processing and
splicing were found in the repressed gene signatures [43].
Second, we have evaluated our new temporal signatures with
other previously published in vitro and in vivo hypoxia signatures
in a much larger cohort of breast cancer patients than done previ-
ously. Surprisingly, we found that even with the inclusion of the
new signatures, none of the in vitro derived signatures consisting
of hypoxia-induced genes are prognostic. This result contrasts with
previous studies [13,15–17], including our own focusing on early
responding hypoxia induced genes. This result stresses the impor-
tance of validation, and likely results from the fact that the number
of patients evaluated in these early studies was limited to a few
hundred. In this study we combined a large number of datasetsto create a highly powered dataset, comprising data on more than
2300 breast cancer patients.
The failure of these in vitro signatures contrasts with the strong
prognostic performance of the three in vivo derived hypoxia signa-
tures, which were clearly able to split patients in groups with dif-
ferent survival properties (Supplementary Fig. 4). This was
somewhat surprising given that the in vivo derived signatures are
derived from and consist of several known hypoxia-induced genes
[16,17,20]. One possibility was that the in vivo signatures reﬂected
biological characteristics distinct from hypoxia itself. For example,
the in vitro studies do not capture the more complex tumour
microenvironment associated with hypoxia. Tumour hypoxia is of-
ten associated with changes in pH, nutrient gradients, and waste
gradients that can inﬂuence gene-expression in important ways
[19,44–46]. It is also possible that tumour hypoxia in vivo is asso-
ciated with over-expression of speciﬁc genes that themselves are
not hypoxia regulated. Such genes could, for example, inﬂuence
the tolerance of hypoxic cells. However, it is unlikely that this is
the primary basis for the difference in the prognostic value of the
signatures. Our analysis demonstrates clearly that the hypoxia-
regulated genes in the in vivo signature contribute to the prognos-
tic power of the signature (Fig. 5C). Since these hypoxia-regulated
genes are included within several of our new signatures, we must
conclude that many other of the co-regulated hypoxia-induced
genes in the in vitro signatures do not contribute to the prognostic
value of hypoxia. Thus, it will be important to identify the fraction
of ‘clinically relevant’ hypoxia regulated genes from the larger frac-
tion of co-regulated genes in vitro for use as a predictor of patient
prognosis.
Finally, our results also indicate that signatures derived from
in vitro hypoxia repressed genes also exhibit prognostic power. Hy-
poxia repressed genes and their clinical importance have not been
assessed to the same extent as hypoxia-induced genes. This is lar-
gely due to the perceived importance of the HIF pathway in hypox-
ia, which inﬂuences cell biology primarily through increased
transcription [47,48]. However, hypoxia is also an important sup-
pressor of cellular metabolism through mTOR and UPR pathways
[49–51] and this is often associated with repressed gene-expres-
sion and reduced proliferation. It is unlikely that the prognostic
power of these signatures is due to hypoxia itself. Our data indicate
that high expression of the repressed genes in these signatures is
associated with worse survival, which is the opposite of the ex-
pected inﬂuence of tumour hypoxia. The GO and pathway analyses
revealed that a large fraction of the genes in these repressed signa-
tures are involved in cell cycle, suggesting that the signatures may
rather be surrogate markers for proliferation. This agrees with
numerous previous publications implicating proliferation in breast
cancer as a major contributor to the prognostic value of gene-
expression microarray-based signatures [14,52].
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